It is used to treat osteoporosis in postmenopausal women and to prevent bone complications (for example, bone fractures, etc.) in the presence of breast cancer that has spread to the bone (bone metastases). , ibandronic acid can be administered orally or parenterally (intravenously).
In commercial medicines, the active ingredient is present in the form of sodium ibandronate.
The method of dispensing depends on the type of medicine taken into consideration and its indications: medicines that can be administered parenterally are for hospital use only; ibandronic acid - ibandronate medicines for oral use used in the prevention of complications in case of bone metastases can be dispensed on presentation of a non-repeatable limitative medical prescription or RNRL (drugs that can be sold to the public only on prescription from hospitals or specialists) ; while the oral medicines indicated for the treatment of osteoporosis can be dispensed upon presentation of a repeatable medical prescription (RR). - Oral ibandronate can be paid for by the National Health System (NHS).
